Manifest / 06
BPC-157 TB-500: frequently asked questions
Direct answers, logged to source. Safety, mechanism, dosing context, and the regulatory record for the two-peptide Wolverine blend.
What the blend is
The definitional questions, answered from the chemistry and the literature.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity and not an approved product [6]. Each peptide has its own sequence, mass, and mechanism; the "blend" is a co-formulation or co-administration convention, not a unified molecule.
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV, ~1419.5 Da) derived from a human gastric-juice protein — the cytoprotective and angiogenic component [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, ~889 Da) from the actin-binding region of Thymosin Beta-4 — the cell-migration component [7].
What is the BPC-157 and TB-500 blend used for in research?
In preclinical research the two peptides are studied for tissue repair: BPC-157 in tendon, ligament, muscle, and wound models [1]; TB-500 / Thymosin Beta-4 in wound, angiogenesis, and cell-migration models [4]. These are animal-model findings in the individual constituents, not human indications for the blend.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid gastric-juice-derived peptide acting as a local cytoprotective and angiogenic signal [2]. TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting intracellularly by sequestering G-actin [3]. Different sequences, different masses, different mechanisms.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) while TB-500 supplies an actin-sequestration signal driving cell migration [2][3]. The complementarity is theoretical; no controlled combination study has defined a synergistic dose, ratio, or endpoint [11].
How it works and what the evidence shows
The mechanism and evidence questions.
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the actin dynamics that drive cell migration [3]. Crystallography of a gelsolin-domain-1-Thymosin-Beta-4-actin complex established this structural basis [3].
How does BPC-157 work compared to TB-500?
BPC-157 acts on vasculature and tissue via VEGFR2-Akt-eNOS angiogenic and cytoprotective signaling and growth-hormone-receptor sensitization [2]; TB-500 acts intracellularly by sequestering G-actin [3]. They are described as complementary but largely non-overlapping pathways.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In preclinical models both do, by distinct routes: BPC-157 via VEGFR2 up-regulation and internalization and the VEGFR2-Akt-eNOS pathway [2], and TB-500 / Thymosin Beta-4 via endothelial migration [4]. This shared vascular thread is part of the combination rationale.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together [11]. The 2025 systematic review of BPC-157 (36 studies, 1 human) makes no mention of TB-500 or combination use [10]. "Synergy" is an extrapolation from each peptide's separate mechanism.
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination for any indication [11]. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies, and "TB-500" human data are for full-length Thymosin Beta-4, not the 7-mer [12].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of transected rat Achilles tendon and improved rat medial collateral ligament healing [1], and TB-500 / Thymosin Beta-4 enhanced ligament healing in rats [4]. These are preclinical, single-compound results, not human evidence for the blend.
Does BPC-157 and TB-500 help muscle tears and recovery?
BPC-157 has been studied in rat muscle-crush and myotendinous-junction models [1], and Thymosin Beta-4 acts as a myoblast chemoattractant [4]. A notable null result: chronic Thymosin Beta-4 in mdx mice increased regenerating fibers but did not improve strength [9].
Does the BPC-157 TB-500 blend help wound healing?
In animal models, Thymosin Beta-4 increased re-epithelialization, wound contraction, collagen deposition, and angiogenesis [4], and BPC-157 shows multi-tissue cytoprotective repair [1]. These are preclinical, single-compound findings, not human evidence for the blend.
Safety and the tumor-signal concern
The safety questions are answered as documented considerations, not as demonstrated human outcomes.
What are the side effects of BPC-157 and TB-500?
There are no controlled human safety data for the blend; human data exist only for the individual constituents and are thin [12]. Combining two unapproved peptides doubles the uncertainty. A documented theoretical concern is the pro-angiogenic, pro-metastatic tumor signal associated with Thymosin Beta-4 [8].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis in laboratory models; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [8]. This is a documented safety consideration, not a demonstrated clinical outcome in humans.
Is the BPC-157 / TB-500 blend safe for long-term use?
Long-term safety of the combination has not been studied in humans [11]. Both constituents are investigational and unapproved, and community "loading then maintenance" protocols have no controlled-trial basis [12]. The blend's long-term safety is unknown.
Is TB-500 bad for your heart?
Full-length Thymosin Beta-4 has been studied for cardiac repair in animal models (PINCH-ILK-Akt cell-survival signaling) [4], but the TB-500 fragment has no controlled human cardiac safety data [12]. No human cardiac harm or benefit is established for the blend.
Dosing context and regulatory status
The dosing and regulatory questions. Dosing answers are research-handling context, never human guidance.
What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog PK study [1]. Human IV Thymosin Beta-4 showed dose-proportional PK, but no specific half-life is established for the TB-500 heptapeptide [12].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [6]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [7]. Described for research handling, not human dosing.
How often should you inject BPC-157 and TB-500?
There is no validated dosing frequency for the blend in humans. Underlying animal studies used a range of schedules — for example, 150 microg twice weekly intraperitoneally over six months for Thymosin Beta-4 in mdx mice [9]. Community frequency protocols have no controlled-trial basis [12].
How do you cycle BPC-157 and TB-500?
No controlled human cycling protocol exists. Community "loading then maintenance" schemes are not validated [12], and a rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — a higher dose gave no benefit — undermining "more is better" loading rationales [13].
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and both are prohibited by WADA [15]. BPC-157 falls under the S0 non-approved-substances category; TB-500 / Thymosin Beta-4 falls under prohibited peptide, growth-factor, and tissue-repair categories [14]. FDA also placed both in 503A Category 2 for compounding [16].
Is Wolverine legal?
Neither of Wolverine's components — BPC-157 or TB-500 — is an FDA-approved drug, and both currently sit in FDA's 503A Category 2 (bulk substances identified as possibly presenting significant safety risks), so compounding-pharmacy access is restricted [P2]. Both are also on the WADA Prohibited List. See the legal-status page for detail; this is general information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
Access is currently restricted. FDA placed BPC-157 in 503A Category 2, which is not covered by FDA's enforcement-discretion policy for compounding [P2]. BPC-157 is on the agenda of a Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026 as a candidate for the 503A bulks list — a scheduled discussion, not a decision [P3].
What is the FDA 503A status of Wolverine?
Both of Wolverine's components are in 503A Category 2, effective with FDA's September 29, 2023 update to the nominated-substances list — meaning they are not within FDA's enforcement-discretion policy for compounding [P2]. Both BPC-157 and TB-500 are scheduled for discussion at the July 23-24, 2026 PCAC meeting as bulks-list candidates [P3].